Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669432 | 0.89 | RAB9A (0.57) | RAB9AGPR35ALDH1A1TDP1TSHR | |
| SCHEMBL3631144 | 0.84 | MAPT (0.44) | RAB9AGPR35NPC1ALDH1A1TDP1 | |
| SCHEMBL8748916 | 0.83 | RAB9A (0.52) | RAB9AGPR35NPC1ALDH1A1TDP1 | |
| SCHEMBL29162289 | 0.83 | RAB9A (0.59) | RAB9AGPR35NPC1ALDH1A1TDP1 | |
| SCHEMBL9501876 | 0.81 | RAB9A (0.51) | RAB9AGPR35ALDH1A1TDP1TSHR | |
| SCHEMBL308233 | 0.81 | MAPT (0.60) | RAB9AGPR35NPC1ALDH1A1TDP1 | |
| SCHEMBL29566643 | 0.81 | MAPT (0.60) | RAB9AGPR35NPC1ALDH1A1TDP1 | |
| SCHEMBL307956 | 0.81 | RAB9A (0.55) | RAB9ANPC1ALDH1A1TDP1TSHR | |
| SCHEMBL27988404 | 0.81 | RAB9A (0.51) | RAB9AGPR35ALDH1A1TDP1TSHR | |
| SCHEMBL3041310 | 0.81 | RAB9A (0.51) | RAB9AGPR35ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| CN-101328150-A | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | claimed |
| CN-100413849-C | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | CN | claimed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| CN-100413849-C | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | CN | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | RAB9A 2667/4885GPR35 1051/4885NPC1 2408/4885 |
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | RAB9A 375/4885GPR35 2820/4885NPC1 1202/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | RAB9A 2722/4885GPR35 1460/4885NPC1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.